3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Phase 1
1
Status
Unknown
1
Completed
1
Sponsor Class
OTHER
1
NETWORK
1
Study Type
Interventional
2
Sponsor
Cancer Type
Sarcoma
2
Conditions
Sarcoma
32
Ovarian Neoplasms
12
Leiomyosarcoma
12
Liposarcoma
10
Neoplasms
7
Sarcoma, Ewing
4
Neoplasm Metastasis
4
Liposarcoma, Myxoid
4
Sarcoma, Synovial
3
Rhabdomyosarcoma
3
Histiocytoma, Malignant Fibrous
3
Breast Neoplasms
3
Solitary Fibrous Tumors
2
Sarcoma, Alveolar Soft Part
2
Prostatic Neoplasms
2
Osteosarcoma
2
Neurofibrosarcoma
2
Neoplasms by Site
2
Mesothelioma, Malignant
2
Malignant mesenchymal tumor
2
Ichthyosis, X-Linked
2
Hemangiosarcoma
2
Hemangiopericytoma, Malignant
2
Fibrosarcoma
2
Fallopian Tube Neoplasms
2
Endometrial Neoplasms
2
Bone Neoplasms
2
Wilms Tumor
1
Uterine Neoplasms
1
Unspecified Childhood Solid Tumor, Protocol Specific
1
Interventions
Ibandronic Acid
8
Gemcitabine
8
Doxorubicin
6
Cyclophosphamide
6
Zoledronic Acid
5
Radiation
4
Nivolumab
4
Irinotecan
4
pembrolizumab
3
Vincristine
3
Temozolomide
3
Magnetic Resonance Spectroscopy
3
Ipilimumab
3
Docetaxel
3
Cisplatin
3
3-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5H-(1,3)dioxolo(4,5-f)indol-7-yl)-pyrrole-2,5-dione
3
regorafenib
2
pegfilgrastim
2
Tranexamic Acid
2
Trabectedin
2
Sunitinib
2
Standard of Care
2
Radiotherapy, Intensity-Modulated
2
Radiotherapy
2
Radiosurgery
2
Proton Therapy
2
Methotrexate
2
Injections
2
Ifosfamide
2
Etoposide
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Interventional
×
Bone Neoplasms
×
Trabectedin
×
Clear all
NCT05131386
2023-03-27
SYNERGIAS
Grupo Espanol de Investigacion en Sarcomas
Phase 2
Unknown
85 enrolled
NCT02398058
2021-04-14
TOMAS
Italian Sarcoma Group
Phase 1
Completed
50 enrolled